证券代码：300233 证券简称：金城医药 公告编号：2020-113 山东金城医药集团股份有限公司 关于参加山东辖区上市公司 2020 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的互动交流，山东金城医药集团股份有限公司 （以下简称"公司"）将于 2020 年 9 月 29 日（星期二）下午 15:00-16:55 参加 "山东辖区上市公司 2020 年度投资者网上集体接待日"活动，现将有关事项公 告如下： 本次投资者网上集体接待日活动将通过网上平台采取网络远程的方式举行， 投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）参与本次投资 者网上接待日活动。 公司副总经理、董事会秘书朱晓刚先生、证券事务代表倪艳莉女士将通过网 络在线形式与投资者进行沟通交流，欢迎广大投资者积极参与。 特此公告。 山东金城医药集团股份有限公司董事会 2020 年 9 月 24 日 ...

山东金城医药集团股份有限公司 2020 年半年度报告全文 山东金城医药集团股份有限公司 2020 年半年度报告 2020 年 08 月 1 山东金城医药集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、发展战略等方面的内容，均不构成本公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险意识，并且 应当理解计划、预测和承诺之间的差异，注意投资风险。 | --- | |-----------------------------------------------------------------------| | | | 公司可能存在产品质量风险、产品销售价格波动的风险、安全环保等相关 | | 风险，具体风险详见第四节 ...

Financial Performance - The company's operating revenue for 2019 was ¥2,794,819,332.70, a decrease of 7.09% compared to ¥3,007,968,049.52 in 2018[22] - The net profit attributable to shareholders for 2019 was ¥203,285,186.73, down 22.96% from ¥263,863,408.96 in the previous year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥64,621,883.15, a decline of 74.25% compared to ¥251,001,639.97 in 2018[22] - The basic earnings per share for 2019 were ¥0.52, a decrease of 22.39% from ¥0.67 in 2018[22] - The diluted earnings per share also stood at ¥0.52, down 22.39% compared to ¥0.67 in the previous year[22] - The weighted average return on equity was 5.47%, down from 6.54% in 2018[22] - The total operating revenue for 2019 was ¥2,794,819,332.70, a decrease of 7.09% compared to ¥3,007,968,049.52 in 2018[92] - The pharmaceutical manufacturing sector contributed 100% to the total revenue, with a year-on-year increase of 5.11%[92] - Domestic sales accounted for 72.31% of total revenue at ¥2,020,960,533.47, down 9.22% from the previous year[92] - The gross profit margin for the pharmaceutical manufacturing sector was 58.47%, an increase of 3.38% year-on-year[96] Cash Flow and Assets - The net cash flow from operating activities increased by 64.11% to ¥577,983,378.38 from ¥352,196,534.35 in 2018[22] - The total assets at the end of 2019 were ¥5,592,390,582.02, reflecting a growth of 5.78% from ¥5,286,594,879.00 at the end of 2018[22] - The net assets attributable to shareholders increased by 1.36% to ¥4,064,167,519.74 from ¥4,009,478,306.73 in 2018[22] - Cash and cash equivalents increased by CNY 26,702.99 million, a growth of 36.93% from the beginning of the year, primarily due to performance compensation received and increased sales collections[49] - The total cash and cash equivalents increased by 804.63% to ¥264,987,727.24[114] - The company's fixed assets amounted to ¥1,373,116,851.43, which is 24.55% of total assets[117] Research and Development - Research and development expenditure increased by 119.09% compared to the previous year, driven by new product development and consistency evaluation investments[52] - The company has been actively expanding its product line, focusing on antibiotics and specialty pharmaceuticals, with key products including cephalosporin intermediates and injectable powder preparations[39] - The company aims to enhance its R&D capabilities and has established a dedicated team for active pharmaceutical ingredients, aligning with its strategic goal of improving product quality[39] - The company implemented a three-dimensional R&D model, with R&D investment increasing by over 10% year-on-year, enhancing innovation capabilities[63] - The total number of R&D personnel increased to 467, representing 15.45% of the workforce[110] - The company's research and development expenses reached ¥263,916,394.24, an increase of 21.00% compared to the previous year[108] Market and Product Development - The company has established three major marketing platforms to enhance product marketing capabilities and achieve collaborative development, maintaining a leading market share in the pharmaceutical and biopharmaceutical sectors[64] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2021[79] - New product development includes a focus on antibiotic formulations, with three new patents filed in 2019[80] - The company plans to implement a new digital marketing strategy to increase brand awareness and customer engagement by 30% in 2020[79] - The company has introduced five new human resource management systems and initiated a talent recruitment plan, bringing in 2 PhDs and 32 Master's graduates during the reporting period[68] Acquisitions and Investments - The company completed the acquisition of 84% equity in Zhejiang Pangu Pharmaceutical Co., Ltd., which is expected to improve overall management efficiency and resource allocation[72] - The company made a significant equity investment of ¥165,000,000 in Zhejiang Pangu, acquiring a 67.35% stake[124] - The company acquired 67.35% of "Pangu Pharmaceutical" for ¥165 million, expanding its consolidation scope[102] Risks and Challenges - The company faces risks from policy changes in the pharmaceutical industry, including the impact of drug price controls and procurement policies[192] - Market risks include fluctuations in raw material prices and competition affecting drug pricing, which could impact profit margins[193] - The acquisition of 100% equity in Langyi Pharmaceutical has resulted in significant goodwill, which poses a risk of impairment if expected earnings are not realized[196] - The company is preparing for potential risks from changes in export tax rebate rates and exchange rate fluctuations by employing hedging tools and adjusting contract terms[198] Compliance and Certifications - All production facilities have passed national GMP certification, ensuring compliance with quality standards in the pharmaceutical manufacturing process[45] - The company has received the "2019 National Level Environment-Friendly Enterprise Pilot Unit" honor and all subsidiaries in the pharmaceutical and chemical sector have been recognized as secondary enterprises for standardized safety production[65] Strategic Goals - The company aims to enhance its product innovation capabilities and increase R&D investment, focusing on high-end pharmaceutical products and high-quality antibiotics[189] - In 2020, the company plans to improve its operational capabilities and risk control systems to ensure steady growth in revenue and profits[185] - The company will implement a "chain forging project" to integrate resources across R&D, marketing, and production, enhancing its competitive advantage in the pharmaceutical industry[191]

山东金城医药集团股份有限公司 2019 年半年度报告全文 山东金城医药集团股份有限公司 2019 年半年度报告 2019 年 08 月 1 山东金城医药集团股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、发展战略等方面的内容，均不构成本公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险意识，并且 应当理解计划、预测和承诺之间的差异，注意投资风险。 公司可能存在产品质量风险、产品销售价格波动的风险、安全环保等相关 风险，具体风险详见第四节经营情况讨论与分析部分"公司面临的风险和应对 措施"中可能面临的主要风险。本报告中如有涉及未来的计划、发展战略等方 面的内容，均不构成本公司对投资者的实质承诺，敬请广大投资者注意投资风 ...

山东金城医药集团股份有限公司 2019 年第三季度报告全文 山东金城医药集团股份有限公司 2019 年第三季度报告 2019 年 10 月 1 山东金城医药集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------------------------------------------|-- ...

Financial Performance - Total operating revenue for Q1 2020 was CNY 650,685,404.33, an increase of 2.57% compared to CNY 634,385,558.13 in the same period last year[8]. - Net profit attributable to shareholders was CNY 101,030,988.13, reflecting a growth of 3.02% from CNY 98,071,895.99 year-on-year[8]. - Net profit after deducting non-recurring gains and losses reached CNY 99,564,127.60, up by 4.53% from CNY 95,248,544.54 in the previous year[8]. - Basic earnings per share increased to CNY 0.26, a rise of 4.00% compared to CNY 0.25 in the same quarter last year[8]. - The total profit for the current period is 120,290,804.99, slightly higher than 116,370,495.72 from the previous period, marking an increase of around 3.5%[130]. - The total comprehensive income attributable to the parent company's owners is 101,030,988.13, compared to 98,071,895.99 in the previous period, indicating an increase of approximately 3%[136]. Cash Flow - The net cash flow from operating activities was CNY 82,376,320.62, down by 3.66% from CNY 85,502,208.63 in the previous year[8]. - Cash inflow from operating activities totaled 540,843,636.84, a decrease from 551,926,086.69 in the previous period[141]. - Cash outflow from operating activities was 458,467,316.22, slightly down from 466,423,878.06 in the previous period[144]. - The cash and cash equivalents at the end of the period amounted to 1,001,465,378.99, up from 739,810,128.59 in the previous period[147]. - The cash flow from operating activities for the parent company was -10,817,347.95, compared to -4,325,123.38 in the previous period[148]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,605,609,774.13, a slight increase of 0.24% from CNY 5,592,390,582.02 at the end of the previous year[8]. - Total liabilities decreased from CNY 1,507,551,708.18 to CNY 1,443,919,651.63, a reduction of approximately 4.24%[114]. - Total equity increased from CNY 4,084,838,873.84 to CNY 4,161,690,122.50, reflecting a growth of about 1.89%[117]. - The company's accounts receivable decreased to CNY 688.65 million as of March 31, 2020, from CNY 715.89 million at the end of 2019, reflecting a decrease of approximately 3.2%[108]. Inventory and Contract Liabilities - Contract liabilities decreased by 58.30% to approximately 15.57 million yuan, primarily due to a reduction in advance payments from customers[24]. - Inventory shares increased by 57.94% to approximately 70.98 million yuan, mainly due to stock repurchases during the reporting period[24]. Research and Development - Research and development expenses decreased by 58.98% to approximately 23.71 million yuan, attributed to reduced R&D investments[25]. - The company has increased investment in product quality R&D to meet national standards and accelerate new product development[36]. Shareholder Information - The top ten shareholders held a combined 80.05% of the company's shares, with Beijing Jingsheng Investment Center holding the largest share at 25.05%[13]. Risk Management - The company faced risks related to pharmaceutical industry policies, including the impact of price reductions and procurement policies on drug sales[32]. - The company is implementing measures to mitigate risks associated with accounts receivable, including credit assessments and insurance[39]. - The company is actively responding to risks related to market supply and demand, raw material prices, and national policies, aiming to optimize production processes and improve gross profit margins[35]. Investment and Projects - The total amount of raised funds is 81,736.99 million, with 21.86% of the total amount being redirected for other uses[47]. - The AE-Active Ester new process project has achieved a completion rate of 96.87% with an investment of 7,900.96 million[47]. - The company adjusted the investment amount for the Cangzhou raw material project from 15,231.98 million to 7,771.88 million due to market changes[56].

山东金城医药集团股份有限公司 2019 年年度报告全文 山东金城医药集团股份有限公司 2019 年年度报告 2020 年 04 月 1 山东金城医药集团股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异，注意投资风险。 | --- | --- | --- | |-------|-------|----------------------------------------------------------------------------| | | | | | | | 公司可能存在产品质量风险、产品销售价格波 ...

山东金城医药集团股份有限公司 2019 年第三季度报告全文 山东金城医药集团股份有限公司 2019 年第三季度报告 2019 年 10 月 1 山东金城医药集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2019 年第三季度报告全文 □ 是 √ 否 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | |--------|---------------------------------------------------------------------------------------------|-- ...

山东金城医药集团股份有限公司 2019 年半年度报告全文 山东金城医药集团股份有限公司 2019 年半年度报告 2019 年 08 月 1 山东金城医药集团股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、发展战略等方面的内容，均不构成本公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险意识，并且 应当理解计划、预测和承诺之间的差异，注意投资风险。 公司可能存在产品质量风险、产品销售价格波动的风险、安全环保等相关 风险，具体风险详见第四节经营情况讨论与分析部分"公司面临的风险和应对 措施"中可能面临的主要风险。本报告中如有涉及未来的计划、发展战略等方 面的内容，均不构成本公司对投资者的实质承诺，敬请广大投资者注意投资风 ...

山东金城医药集团股份有限公司 2019 年第一季度报告全文 山东金城医药集团股份有限公司 2019 年第一季度报告 2019 年 04 月 1 山东金城医药集团股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | |-------|--------------|-------|-----------------------------------------------------|------------------|--------- ...